Drug maker Valeant in talks on $13 billion Actavis buy: source Sat Apr 27, 2013 9:14am EDT (Reuters) - Canada's largest listed drug maker, Valeant Pharmaceuticals International Inc, is in talks to buy generic drugmaker Actavis Inc for more than $13 billion, a person familiar with the situation told Reuters on Friday night. It is not clear how advanced the discussions are and a deal could still fall through, said the source, who declined to be identified because they are not allowed to speak to the media. A Valeant spokeswoman declined to comment and an Actavis spokesman could not be reached for comment outside of business hours. The Wall Street Journal first reported the talks between the two companies on Friday. Reporting by Soyoung Kim, writing by Jessica Toonkel; Editing by Sandra Maler